Literature DB >> 31883083

Studying Evolutionary Adaptation of MERS-CoV.

Michael Letko1, Vincent Munster2.   

Abstract

Forced viral adaptation is a powerful technique employed to study the ways viruses may overcome various selective pressures that reduce viral replication. Here, we describe methods for in vitro serial passaging of Middle East respiratory syndrome coronavirus (MERS-CoV) to select for mutations which increase replication on semi-permissive cell lines as described in Letko et al., Cell Rep 24, 1730-1737, 2018.

Entities:  

Keywords:  Cell culture; Experimental evolution; Forced adaptation; Host restriction; MERS-CoV; Semi-permissive cell line; Species barrier

Mesh:

Year:  2020        PMID: 31883083      PMCID: PMC7121928          DOI: 10.1007/978-1-0716-0211-9_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


Introduction

RNA viruses are ideal model organisms to study evolutionary genetics under selection. This is due to their large population sizes and short generation times, which are characterized by rapid accumulation of mutations relative to other organisms. Given the error-prone nature of viral RNA-dependent RNA polymerases, viral replication leads to the formation of a quasispecies [1-3]. Rather than one virus producing identical progeny during replication, a population of viruses is produced, each differing from one another by nucleotide substitutions or deletions as a result of errors incorporated by the RNA polymerase. While the majority of these mutations will have neutral or negative effects on viral fitness, a small subset of these mutations may prove beneficial and enhance the ability for certain variants to replicate despite selective pressures of interest such as the host immune response or an antiviral drug. Forced adaptation experiments have been used to determine viral mutations that facilitate escape from drugs [4-6], monoclonal antibodies [7, 8], host restriction factors [9-11], and species variation in host receptors [12-14] and to elucidate various viral mechanisms of infection and replication [15-17]. Within the laboratory setting, the strength of selective pressure can be adjusted by increasing or decreasing the levels of the restrictive factor, thus facilitating the rapid expansion of viral variants within the population of quasispecies that can overcome the applied selective pressure. The ideal environment is “semi-permissive”—allowing only low levels of wild-type virus replication. Below is the method employed to adapt MERS-CoV to a semi-permissive host receptor, Desmodus rotundus DPP4 . The techniques described below could be applicable to a wide range of experiments to better understand the adaptive capacity of various coronaviruses under specific selective pressures.

Materials

Cell Culture

Semi-permissive cells: baby hamster kidney (BHK) cells which have been transduced to stably express Desmodus rotundus DPP4 (drDPP4 [12]. Briefly, the coding sequence for drDPP4 was cloned into a lentiviral expression cassette also encoding for mcherry-T2A-puromycin-N-acetyltransferase-P2A (System Biosciences) and used to generate lentiviral particles [9] (see Note 1). BHK cells were infected with lentiviral particles and then grown in DMEM containing puromycin at a final concentration of 1 ug/mL. Cell culture media: Dulbecco’s Modified Eagles Medium (DMEM), 10% fetal bovine serum, 1% l-glutamine, 1% penicillin and streptomycin, and 1 μg/mL puromycin. Passaging culture media: Dulbecco’s Modified Eagles Medium (DMEM), 2% fetal bovine serum, 1% l-glutamine, 1% penicillin and streptomycin, and 1 μg/mL puromycin. Light microscope to check cell cultures for cytopathic effects .

Passaging Experiment

6-Well cell-culture cluster plates. MERS-CoV/EMC2012, passage 6. This virus stock was grown in-house and titered by standard endpoint titration on Vero cells [18].

Directed Sequencing of MERS-CoV Spike

Viral RNA extraction mini kit. Superscript IV reverse transcriptase cDNA production kit. iProof High-fidelity PCR kit. Agarose gel purification kit. MERS-CoV Spike receptor-binding domain sequencing primers (see Table 1).
Table 1

Primers for sequencing MERS-CoV spike

Primer numberPrimer sequencePrimer orientation
1ATGATACACTCAGTGTTTCTForward
2TAGAAGGCAGCCCAAGCTTTTReverse
3TTACGTAACTGCACCTTTATGForward
4CATTTCACCTGGAACAGAGCReverse
5AGATTCTACATATGGCCCCCTForward
6TTAGTGAACATGAACCTTATGCGGCReverse
Sequence analysis software capable of multiple sequence alignment and viewing chromatograms. Primers for sequencing MERS-CoV spike

Methods

Prepare Cells for Viral Passaging

Plan number of conditions. At least three replicates (well of semi-permissive cells) for each forced adaptation experiment should be performed in parallel. Critically, parental cells or a cell line stably expressing an irrelevant protein should be included to control for any nonspecific cell culture mutations. Grow semi-permissive BHK cells to confluency in appropriate format. One 75 cm2 flask should be sufficient to seed at least three 6-well cluster plates. Wash, trypsinize, count, and seed BHK cell lines (parental controls and semi-permissive) in cell culture media (10% FBS) at a density of 1.5 × 105 cells/mL in a 2 mL volume in each well of 6-well plates (see Note 2).

Infect Cells

Twenty-four hours later, replace media on seeded cell lines with 2 mL of fresh passaging culture media (2% FBS). Infect cells with MERS-CoV/EMC2012 at a final MOI of 0.01 (Fig. 1).
Fig. 1

Transduced cells are infected with wild-type stock. Approximately 72 hours later, supernatant from the infected cells is used to infect fresh cells as passage one. The process is repeated until the formation of cytopathic effects in culture. Supernatant from each passage is sequenced to detect the presence of adaptive mutations

Transduced cells are infected with wild-type stock. Approximately 72 hours later, supernatant from the infected cells is used to infect fresh cells as passage one. The process is repeated until the formation of cytopathic effects in culture. Supernatant from each passage is sequenced to detect the presence of adaptive mutations

Prepare Cells for Subsequent Passage and Passage Virus

After 48 h postinfection, prepare new cell culture plates to passage virus. Follow initial seeding conditions and plate at a density of 1.5 × 105 cells/mL in a 2 mL volume in each well of 6-well plates. Twenty-four hours after seeding the new cells (72 h postinfection of previous culture), replace media on seeded cell lines with 2 mL of fresh passaging culture media (2% FBS). After 72 h postinfection for previous culture, take a 500 μL of supernatant sample from the infected culture and store for downstream viral sequencing. Store supernatants at −80 °C. Check previously infected cells for emergence of cytopathic effects (cell death, rounding-up, and detachment from cell culture plate in more than 50% of individual cultures) (see Note 3). If cytopathic effects are observed, this is strongly suggestive of viral adaptation to the semi-permissive cells. Proceed with step 3.4. Subsequent passages may be performed to select for further mutations that enhance viral replication in the semi-permissive cells (see Note 4). If no cytopathic effects are observed, then begin next viral passage: from the previously infected culture, transfer 250 μL of supernatant to the new cell cultures seeded the day before. Discard previously infected culture. Repeat steps 1–6 until cytopathic effects are observed, indicative of viral adaptation.

Extract Viral RNA and Sequence Spike

Extract RNA from stored supernatants using the Qiagen viral RNA miniprep kit (Qiagen), following manufacturer’s instructions. Generate cDNA from extracted RNA using Superscript IV, following manufacturer’s instructions. Amplify select regions from viral cDNA using iProof high-fidelity PCR polymerase kit (Bio-Rad). Below are example PCR conditions for amplifying the MERS-CoV receptor-binding domain following the primer numbers listed in Subheading 2.2.5 of [12] (see Table 2).
Table 2

Primer pairs and expected product sizes for tiled MERS-CoV spike PCR amplification

Forward primerReverse primerExpected PCR product size (bp)
12940
341571
562447
PCR Cycling conditions Gel purify PCR amplicons from 1% agarose using gel purification kit and following manufacturer’s instructions. Send each product for Sanger sequencing. Check Sanger sequencing chromatograms for overlapping peaks, indicative of mutations within a mixed viral population, as further described in [12] Primer pairs and expected product sizes for tiled MERS-CoV spike PCR amplification

Notes

Importantly, this specific lentivector cassette is expressed under the Ef1α promoter, which allows for mid-level expression of the transgene as compared to other popular lentiviral transgene promoters such as CMV or CAGGS. This midlevel expression is ideal for semi-permissive selective pressure created by the transgene, in this case, drDPP4 . The plating density of cells may vary from this suggested value, depending on growth kinetics. In general, cells should be plated to achieve approximately 80–90% confluency on the day of infection. Cytopathic effects may be gradual to appear. To increase selective pressures on a viral population which is beginning to show signs of adaptation, one can apply a population bottleneck in the subsequent passage by reducing the amount of viral supernatant passaged to the next cell culture. In this case, we recommend reducing the passage volume by approximately tenfold. In our initial study [12], cytopathic effects were observed by the eighth passage; however, sequencing from earlier passages showed adaptive mutations emerging in the culture by the third passage. Depending on the strength of selection, the number of passages required to elicit adaptive mutations will vary.
31.5 μLdiH2O
10 μLiProof buffer
5 μLdNTP mix
1 μLforward primer (10 μM)
1 μLreverse primer (10 μM)
0.5 μLiProof enzyme
1 μLcDNA (from Subheading 3.4, step 2)
TemperatureTime
98 °C3 min
98 °C10 s1.1.40 cycles
50 °C30 s
72 °C30 s
72 °C5 min
10 °CHold
  18 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

Review 2.  Viral quasispecies.

Authors:  Raul Andino; Esteban Domingo
Journal:  Virology       Date:  2015-03-29       Impact factor: 3.616

3.  Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.

Authors:  Michael Letko; Thijs Booiman; Neeltje Kootstra; Viviana Simon; Marcel Ooms
Journal:  Cell Rep       Date:  2015-11-25       Impact factor: 9.423

4.  In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.

Authors:  H Z Bazmi; J L Hammond; S C Cavalcanti; C K Chu; R F Schinazi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  Amino acid substitutions in the S2 subunit of mouse hepatitis virus variant V51 encode determinants of host range expansion.

Authors:  Willie C McRoy; Ralph S Baric
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

6.  Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4.

Authors:  Neeltje van Doremalen; Kerri L Miazgowicz; Shauna Milne-Price; Trenton Bushmaker; Shelly Robertson; Dana Scott; Joerg Kinne; Jason S McLellan; Jiang Zhu; Vincent J Munster
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

7.  In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.

Authors:  Akihiko Sato; Jennifer Hammond; Therese N Alexander; Joanne P Graham; Susan Binford; Ken-Ichi Sugita; Hirohiko Sugimoto; Tamio Fujiwara; Amy K Patick
Journal:  Antiviral Res       Date:  2006-01-25       Impact factor: 5.970

Review 8.  Quasispecies theory and the behavior of RNA viruses.

Authors:  Adam S Lauring; Raul Andino
Journal:  PLoS Pathog       Date:  2010-07-22       Impact factor: 6.823

9.  Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution.

Authors:  Atze T Das; Bep Klaver; Mireille Centlivre; Alex Harwig; Marcel Ooms; Mark Page; Neil Almond; Fang Yuan; Mike Piatak; Jeffrey D Lifson; Ben Berkhout
Journal:  Retrovirology       Date:  2008-06-05       Impact factor: 4.602

10.  Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody.

Authors:  Ning Chai; Lee R Swem; Mike Reichelt; Haiyin Chen-Harris; Elizabeth Luis; Summer Park; Ashley Fouts; Patrick Lupardus; Thomas D Wu; Olga Li; Jacqueline McBride; Michael Lawrence; Min Xu; Man-Wah Tan
Journal:  PLoS Pathog       Date:  2016-06-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.